

IND SAFETY REPORT: INITIAL WRITTEN REPORT**TO: Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9845**

1. IND NUMBER

61010

2. AGENT NAME

CCI-779 (temsirrolimus, Torisel™)

3. DATE

May 19, 2009

4. SPONSOR

Division of Cancer Treatment and Diagnosis, National Cancer Institute

5. REPORTER'S NAME, TITLE, AND INSTITUTION

L. Austin Doyle, MD-Senior Investigator for Targeted Therapeutics 2, Investigational Drug Branch, CTEP, DCTD, NCI

6. PHONE NUMBER

301-496-1196

7. FAX NUMBER

301-402-0428

8. PROTOCOL NUMBER (AE #)

NCIC-160 (1986402)

9. PATIENT IDENTIFICATION

CABN0001

10. AGE

70

11. SEX

Female

12. DESCRIPTION OF ADVERSE EVENT

The patient is a 70-year-old female with endometrial adenocarcinoma who experienced a grade 4 dehydration and grade 3 hyponatremia while on a phase 2 trial using the investigational agent temsirolimus. The patient began the first dose of temsirolimus on September 26, 2006, and received the last dose of temsirolimus on November 7, 2006 (Cycle 1, Day 43). On October 17, 2006 (Cycle 1, Day 22), the patient presented to the clinic with diarrhea. Upon physical examination, the patient was found to be dehydrated, and she was admitted to the hospital. The chemotherapy was held. Laboratory findings showed sodium of 128 mmol/L (reference range: 136-144mmol/L), potassium of 4.0 mmol/L (reference range of 3.6-5.1), anion gap 3 mmol/L (reference range: 7-16 mmol/L). The patient was placed on IV fluids and electrolytes. Her condition had returned to baseline and she was discharged on October 22, 2006. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drug.

13. DOSE, ROUTE, AND SCHEDULE

Temsirolimus 25 mg IV over 30 minutes Days 1, 8, 15, 22 every 4 weeks

14. DATES OF TREATMENT

The patient began the investigational drug therapy on September 26, 2006, and received the last dose of temsirolimus on November 7, 2006 (Cycle 1, Day 43).

15. ACCRUAL AND IND EXPERIENCE

Number of patients enrolled in NCI-sponsored clinical trials using temsirolimus = 1596. There have been 58 other cases of dehydration and 17 other cases of hyponatremia reported to the NCI through AdEERS as serious adverse events for temsirolimus.

16. COMMENTS

AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d)(2).

DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/ SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.